Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Egypt / NCT07114978
Starting soon Observational

Prognostic Value of the LVOT VTI in STEMI Patients Undergoing PPCI

NCT07114978 · tracked via the Priya Life Science Egypt tracker
Sponsor
Assiut University
Phase
Observational
Started
2025-08-01
Last updated
2025-08-11

Condition(s) studied

LVOT VTISTEMI - ST Elevation Myocardial Infarction (MI)Primary Percutaneous Coronary Intervention

Investigational drug(s) / intervention(s)

Echocardiography

Echocardiography: simple, bedsided, non-invasive

Study summary

* To determine whether LVOT VTI \< 15 cm predicts the development of in-hospital cardiogenic shock or need for vasopressors in STEMI patients undergoing primary PCI.
* To assess association of LVOT VTI with other adverse outcomes (in-hospital death, heart failure, arrhythmias, need for mechanical ventilation, prolonged hospital stay).

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Adult patients (≥18 years), diagnosed with acute STEMI according to current ESC guidelines(3) and undergoing primary PCI within 24 hours of symptom onset. 2. Patients undergo transthoracic echocardiography within 24 hours of admission. Exclusion Criteria: 1. Presence of significant aortic valve disease (e.g., severe aortic stenosis or regurgitation). 2. LVOT obstruction or hypertrophic cardiomyopathy. 3. Poor echocardiographic window. 4. Refusal to participate.

Primary outcome measure(s)

  • Incidence of cardiogenic shock in patients with LVOT VTI < 15 cm — Through hospital stay (up to 3 days)
    Cardiogenic shock defined per ESC 2023 criteria (SBP \<90 mmHg for ≥30 minutes plus signs of hypoperfusion, or need for vasopressors/inotropic support). Assessed during hospital stay in relation to baseline LVOT VTI. Unit of Measure: Percentage of patients (%)

Trial sites (1)

FacilityCityRegionStatus
Assiut University Asyut Egypt

More Assiut University trials in Egypt

Predictors of RV Dysfunction After BPV Active, not recruiting
Epidemiological Evaluation of Knee Injuries in Children Admitted to Assiut University Hospitals From 2022 to 2025. Active, not recruiting
Assessment of Cardiac Output and Stroke Volume in Septic Shock Patients Starting soon
Atypical Pneumonia Starting soon
Impact of Aortic Geometry on Vascular Remodeling After Stent Implantation in Coarctation of the Aorta Starting soon

Other trials for the same condition

Short Term Outcomes of Primary Percutaneous Coronary Intervention (PCI) Patients Presented With Acute Heart Failure in Assuit University Heart Hospital Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07114978 on ClinicalTrials.gov ↗ ← All trials in Egypt